30-day adjusted risk ratios for short- versus long-course antibiotic therapy not significant for mortality, readmission, urgent visit ...

Approval was supported by the phase 3 LANDI-PED study, which demonstrated significant heart rate reduction and conversion to normal sinus rhythm in pediatric patients.

Food supplementation not associated with improvement in primary clinical outcomes, but researcher notes improvement in health-related quality of life.

Among those with XDR isolates with species information, 65.9 and 34.1 percent were Shigella sonnei and Shigella flexneri ...

Delgocitinib cream was shown to be effective and well-tolerated in adolescents with chronic hand eczema in the phase 3 DELTA TEEN clinical trial.

The unit-dose amlodipine powder for oral solution provides a stable, preservative-free alternative for patients who struggle with traditional tablet formulations.

Following favorable phase 1 data showing significant reductions in HBV DNA and RNA, the FDA has fast tracked pevifoscorvir sodium for chronic HBV infection.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ulixacaltamide HCl for the treatment of essential tremor in adults. Ulixacaltamid ...

Guidelines also developed for medical management of pediatric atopic dermatitis, including 27 evidence-based recommendations ...

The updated rules were approved by Health Secretary Robert F. Kennedy Jr. and posted in a new charter outlining operation of the panel, which guides vaccine use in the US and advises the US Centers ...

Nephrologists now have an approved treatment option for FSGS patients without nephrotic syndrome following the latest FDA ...

ApoB goal optimal in 65% of probabilistic analyses at willingness-to-pay threshold of $120,000 per QALY gained.